Search Articles and Web Sources

Search Results

In this project

HLK-LD2450: Deep integration with ESPHome and Home Assistant

https://sudonull.com/hlk-ld2450-deep-integration-with-esphome-and-home-assistant

Learn how to fully unlock the potential of the millimeter-wave radar HLK-LD2450. Configure registers, zones, and track Multi-Target targets via ESPHome and Home Assistant using the binary protocol and ESP-IDF.

Moratorium on AI Data Centers in Maine: What Awaits Developers

https://sudonull.com/moratorium-on-ai-data-centers-in-maine-what-awaits-developers

First US State Freezes Data Centers >20 MW Until 2027. Analysis of LD 307, Blockades on $64 Billion and Impact on GPU Prices. How Power Shortages Will Hit AI Projects — Read the Details.

SEO and GEO for Astro site: setup 2026

https://sudonull.com/seo-and-geo-for-astro-site-setup-2026

Set up SEO and GEO on a static Astro site: hreflang, canonical, JSON-LD, Lighthouse. For developers — bilingual blog, POSSE, audit. Learn more.

Syncloud: self-hosting without Docker and configs

https://sudonull.com/syncloud-self-hosting-without-docker-and-configs

How open source platform on Go solves the pain of manual server management. Installation, SSO, HTTPS and updates — without terminal. For devops and senior developers.

From other projects

Cholesterol gene therapy VERVE-102: NEJM data, LDL reduction by 62%

https://ymaho.com/cholesterol-gene-therapy-verve-102-nejm-data-ldl-reduction-by-62

NEJM published phase 1b results of gene therapy VERVE-102: LDL reduction by 62% after a single injection. Analysis of efficacy, risks, and prospects for patients with hypercholesterolemia. Read more.

Bank of England's Largest Liquidity Test of Pension Funds

https://ymaho.com/bank-of-england-s-largest-liquidity-test-of-pension-funds

Bank of England requires LDI funds to double liquidity reserves by September 2026. What are the risks of corporate bond sell-off and currency volatility? Analysis.

CRISPR in vivo reduces cholesterol by 60% in VERVE-102 study

https://ymaho.com/crispr-in-vivo-reduces-cholesterol-by-60-in-verve-102-study

Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.

VERVE-102 gene editing reduces cholesterol by 62% — analysis

https://ymaho.com/verve-102-gene-editing-reduces-cholesterol-by-62-analysis

Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.

AAV gene therapy for HoFH: cholesterol reduction by 97.5% in clinical trial

https://ymaho.com/aav-gene-therapy-for-hofh-cholesterol-reduction-by-97-5-in-clinical-trial

New AAV8 gene therapy NGGT006 for homozygous familial hypercholesterolemia reduced LDL-C by 97.5% in 3 weeks. Effect persists for 52 weeks. Find out who is eligible for treatment.

CRISPR gene editing: treatment of hypertriglyceridemia CTX310

https://ymaho.com/crispr-gene-editing-treatment-of-hypertriglyceridemia-ctx310

CRISPR Therapeutics presented CTX310 — a one-time gene therapy that reduces triglycerides by 82% and LDL by 86%. Learn about the revolution in dyslipidemia treatment and market prospects.

CRISPR therapy VERVE-102 reduces cholesterol by 62% after injection

https://ymaho.com/crispr-therapy-verve-102-reduces-cholesterol-by-62-after-injection

Journal NEJM published data on the drug VERVE-102: a single CRISPR injection (base editing) reduces LDL by 62% for 18 months without serious side effects. Learn details about the revolutionary therapy.